Carnosine exerts antitumor activity against bladder cancers in vitro and in vivo via suppression of angiogenesis.

[1]  G. Aldini,et al.  A carnosine analog mitigates metabolic disorders of obesity by reducing carbonyl stress , 2018, The Journal of clinical investigation.

[2]  Yanrong Chen,et al.  Investigations on in vitro anti-carcinogenic potential of l-carnosine in liver cancer cells , 2018, Cytotechnology.

[3]  S. Culine,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial , 2017, The Lancet.

[4]  Chris Berdik.  Unlocking bladder cancer , 2017, Nature.

[5]  Yung-Hyun Choi,et al.  HSP70-1 is required for interleukin-5-induced angiogenic responses through eNOS pathway , 2017, Scientific Reports.

[6]  K. Trinkaus,et al.  Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. , 2016, Oral oncology.

[7]  K. Książek,et al.  L-Carnosine Prevents the Pro-cancerogenic Activity of Senescent Peritoneal Mesothelium Towards Ovarian Cancer Cells. , 2016, Anticancer research.

[8]  J. Hainsworth,et al.  A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. , 2015, European journal of cancer.

[9]  Jianxin Lu,et al.  Carnosine Inhibits the Proliferation of Human Gastric Cancer SGC-7901 Cells through Both of the Mitochondrial Respiration and Glycolysis Pathways , 2014, PloS one.

[10]  F. Gaunitz,et al.  Inhibition of tumour cell growth by carnosine: some possible mechanisms , 2014, Amino Acids.

[11]  G. Aldini,et al.  Physiology and pathophysiology of carnosine. , 2013, Physiological reviews.

[12]  T. Downs,et al.  Expression Microarray Meta-Analysis Identifies Genes Associated with Ras/MAPK and Related Pathways in Progression of Muscle-Invasive Bladder Transition Cell Carcinoma , 2013, PloS one.

[13]  S. Menini,et al.  D‐carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation , 2012, British journal of pharmacology.

[14]  M. Pricolo,et al.  Carnosine inhibits KRAS-mediated HCT116 proliferation by affecting ATP and ROS production. , 2012, Cancer letters.

[15]  Fa-lin Xu,et al.  Carnosine pretreatment protects against hypoxia-ischemia brain damage in the neonatal rat model. , 2011, European journal of pharmacology.

[16]  K. Bensalah,et al.  Prognostic factors for upper urinary tract urothelial carcinoma , 2011, Nature Reviews Urology.

[17]  G. Aldini,et al.  Design, Synthesis, ADME Properties, and Pharmacological Activities of β‐Alanyl‐D‐histidine (D‐Carnosine) Prodrugs with Improved Bioavailability , 2011, ChemMedChem.

[18]  R. Seiler,et al.  MMP-2 and MMP-9 in lymph-node-positive bladder cancer , 2011, Journal of Clinical Pathology.

[19]  B. Rolando,et al.  Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents. , 2011, Journal of medicinal chemistry.

[20]  Tianhong Li,et al.  A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial , 2010, Investigational New Drugs.

[21]  T. Sato,et al.  Biological Activity of Novel Synthetic Derivatives of Carnosine , 2010, Cellular and Molecular Neurobiology.

[22]  D. Camidge,et al.  Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Hongtao Jia,et al.  Ras-MAPK pathway as a therapeutic target in cancer--emphasis on bladder cancer. , 2009, Recent patents on anti-cancer drug discovery.

[24]  S. Fang,et al.  Carnosine inhibits high glucose-induced mesangial cell proliferation through mediating cell cycle progression , 2009, Regulatory Peptides.

[25]  G. Gillies,et al.  In vitro angiogenesis by human umbilical vein endothelial cells (HUVEC) induced by three-dimensional co-culture with glioblastoma cells , 2009, Journal of Neuro-Oncology.

[26]  R. Sclafani,et al.  Cell cycle regulation of DNA replication. , 2007, Annual review of genetics.

[27]  M. Swellam,et al.  Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. , 2007, European urology.

[28]  J. Huot,et al.  Endothelial cell migration during angiogenesis. , 2007, Circulation research.

[29]  S. Lamy,et al.  A prostate secretory protein94‐derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: Implication in tumor angiogenesis , 2006, International journal of cancer.

[30]  Cheng-chin Hsu,et al.  Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. , 2005, European Journal of Pharmacology.

[31]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[32]  M. Loda,et al.  A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck , 2004, Clinical Cancer Research.

[33]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[34]  J. Blow,et al.  The origin of CDK regulation , 2001, Nature Cell Biology.

[35]  N. Holbrook,et al.  Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[36]  R. Millikan,et al.  The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  H. Haller,et al.  Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways. , 2000, Journal of cell science.

[38]  F. André,et al.  Insulin-like Growth Factor-I Protects Colon Cancer Cells from Death Factor-induced Apoptosis by Potentiating Tumor Necrosis Factor α-induced Mitogen-activated Protein Kinase and Nuclear Factor κB Signaling Pathways , 2000 .

[39]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[40]  C. Marshall,et al.  How do small GTPase signal transduction pathways regulate cell cycle entry? , 1999, Current opinion in cell biology.

[41]  R. Busse,et al.  Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation , 1999, Nature.

[42]  J. Isner,et al.  Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. , 1999, The Journal of clinical investigation.

[43]  D. Grignon,et al.  Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  Vishva Dixit,et al.  Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway , 1998, The Journal of Biological Chemistry.

[45]  E. Levin,et al.  Extracellular Signal-regulated Protein Kinase/Jun Kinase Cross-talk Underlies Vascular Endothelial Cell Growth Factor-induced Endothelial Cell Proliferation* , 1998, The Journal of Biological Chemistry.

[46]  C. Chi,et al.  Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. , 1998, Anticancer research.

[47]  A. Hipkiss,et al.  Toxic effects of β-amyloid(25–35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and β-alanine , 1998, Neuroscience Letters.

[48]  A. Harris,et al.  Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. , 1997, Cancer research.

[49]  A. Mantovani,et al.  Molecular mechanisms of blood vessel formation. , 1997, Trends in biochemical sciences.

[50]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[51]  P. Carroll,et al.  Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. , 1995, The Journal of urology.

[52]  A. Harris,et al.  Different angiogenic pathways characterize superficial and invasive bladder cancer. , 1995, Cancer research.

[53]  A. Hanby,et al.  Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. , 1993, Cancer research.

[54]  J. Richie,et al.  Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. , 1993, Journal of the National Cancer Institute.

[55]  C. Osborne,et al.  Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. , 1983, Cancer research.

[56]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[57]  C. Barrios,et al.  Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3β. , 2014, Urologic oncology.

[58]  P. Jakeman,et al.  Carnosine and anserine concentrations in the quadriceps femoris muscle of healthy humans , 2004, European Journal of Applied Physiology and Occupational Physiology.

[59]  D. Ito,et al.  Effect of 5-fluorouracil on G1 phase cell cycle regulation in oral cancer cell lines. , 2004, Oral oncology.

[60]  N. G. Davydova,et al.  Efficacy of N-Acetylcarnosine in the Treatment of Cataracts , 2002, Drugs in R&D.

[61]  F. André,et al.  Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. , 2000, Cancer research.

[62]  T. Suda,et al.  [Antineoplastic effects of carnosine and beta-alanine--physiological considerations of its antineoplastic effects]. , 1986, Nihon seirigaku zasshi. Journal of the Physiological Society of Japan.